Physician profile
Charles Fulk
NPI 1801848668
$21,715.12
in general payments reported to CMS, 2019-2025
35 companies · $3,234 in 2025
The $3,234 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,020 · 2020: $1,518 · 2021: $1,753 · 2022: $3,658 · 2023: $3,351 · 2024: $4,180 · 2025: $3,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,544.58 |
| Education | $220.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,492.99 | 2019-2025 | |
| Lilly USA, LLC | $3,512.23 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Allergan, INC. | $2,427.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,492.54 | 2019-2025 | |
| Janssen Biotech, INC. | $1,259.90 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $1,247.27 | 2020-2025 | Ilumya, Blu-U, Odomzo |
| Ucb, INC. | $1,144.74 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $835.56 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $602.33 | 2021-2025 | Dupixent, Libtayo |
| Genentech USA, INC. | $597.57 | 2019-2023 | Erivedge |
| Pfizer INC. | $455.57 | 2019-2025 | |
| Genzyme Corporation | $425.22 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $279.73 | 2024-2025 | Acthar |
| Amgen INC. | $243.24 | 2020-2025 | Otezla |
| Novo Nordisk INC | $225.50 | 2024-2025 | Ozempic, Rybelsus |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $223.17 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $200.00 | 2019 | |
| Dermavant Sciences, INC. | $184.11 | 2023-2024 | Vtama |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Arcutis Biotherapeutics, INC. | $101.23 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.01 | 2022-2025 | Spevigo |
| Galderma Laboratories, L.P. | $99.17 | 2021-2025 | Nemluvio |
| Dusa Pharmaceuticals, INC. | $78.97 | 2019 | |
| Dermira, INC. | $62.56 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $56.67 | 2022 | |
| Incyte Corporation | $46.44 | 2022-2023 | Opzelura |
| Leo Pharma INC. | $45.20 | 2020-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.18 | 2019 | |
| Merz North America, INC. | $20.86 | 2021 | |
| Biofrontera INC. | $19.32 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Almirall LLC | $18.59 | 2020 | |
| Organogenesis INC. | $17.94 | 2024 | |
| Celgene Corporation | $17.08 | 2019 | |
| Nabriva Therapeutics, Plc | $13.91 | 2021 | |
| Merck Sharp & Dohme LLC | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Fulk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.